hat
Menm jan ak lòt AAS, oxandrolone ka vin pi mal hypercalcemia pa ogmante absòpsyon zo osteyolitik. Lè yo pran fanm ansent, oxandrolone ka gen efè entansyonel tankou masculinizasyon sou fetis la. Oxandrolone anpil ogmante efè san efè warfarin a, pafwa danjerezman konsa.Nan mwa avril 2004, Savient Pharmaceuticals pibliye yon alèt sekirite nan pwofesyonèl swen sante FDA nan sa a.Oxandrolone kapab tou anpeche metabolis a nan ajan ipoglisemik oral.It ka vin pi mal èdèm lè yo te pran ansanm kortikoterapi oswa òmòn adrenokortikotwòp.
eng
Like other AAS, oxandrolone may worsen hypercalcemia by increasing osteolytic bone resorption. When taken by pregnant women, oxandrolone may have unintended effects such as masculinization on the fetus. Oxandrolone greatly increases warfarin's blood-thinning effect, sometimes dangerously so.In April 2004, Savient Pharmaceuticals published a safety alert through the FDA warning healthcare professionals of this.Oxandrolone can also inhibit the metabolism of oral hypoglycemic agents.It may worsen edema when taken alongside corticosteroids or adrenocorticotropic hormone.